<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fenfluramine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00574</strong>&#160; (APRD00319)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>illicit, withdrawn</td></tr><tr><th>Description</th><td><p>Fenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and pulmonary hypertension, including a condition known as cardiac fibrosis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00574/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00574/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00574.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00574.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00574.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00574.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00574.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00574">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Fenfluramina</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCIT</td></tr><tr><td>Fenfluraminum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Fenfluramine hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000802/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000802/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZXKXJHAOUFHNAS-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 267.100161871</li>
              <li>Average Mass: 267.718</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000802">DBSALT000802</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Adifax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ponderax</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pondimin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Fen-phen</td><td>fenfluramine + phentermine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/serotonin-uptake-inhibitors">Serotonin Uptake Inhibitors</a></li>
<li><a href="/mesh/appetite-depressants">Appetite Depressants</a></li>
<li><a href="/mesh/serotonin-receptor-agonists">Serotonin Receptor Agonists</a></li>
<li><a href="/mesh/serotonin-agents">Serotonin Agents</a></li>
<li><a href="/mesh/stimulants">Stimulants</a></li></ul></td></tr><tr><th>CAS number</th><td>458-24-2</td></tr><tr><th>Weight</th><td>Average: 231.2573<br>Monoisotopic: 231.123484132</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>16</sub>F<sub>3</sub>N</td></tr><tr><th>InChI Key</th><td>DBGIVFWFUFKIQN-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">ethyl({1-[3-(trifluoromethyl)phenyl]propan-2-yl})amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCNC(C)CC1=CC(=CC=C1)C(F)(F)F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenethylamines</td></tr><tr><th>Direct parent</th><td>Amphetamines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Polyamines; Dialkylamines; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>polyamine; secondary aliphatic amine; secondary amine; organonitrogen compound; amine; organofluoride; organohalogen; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the management of exogenous obesity as a short-term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction.</td></tr><tr><th>Pharmacodynamics</th><td>Used to treat obesity, Fenfluramine decreases caloric intake by increasing serotonin levels in the brain's synapses. Fenfluramine acts as a serotonin reuptake inhibitor. It also causes release of serotonin from the synaptosomes. This in turn increases serotonin transmission in the feeding centre of the brain which suppresses appetite.</td></tr><tr><th>Mechanism of action</th><td>Fenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin uptake and release of serotonin. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.</td></tr><tr><th>Absorption</th><td>Fenfluramine is well-absorbed from the gastrointestinal tract, and a maximal anorectic effect is generally seen after 2 to 4 hours.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Fenfluramine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00316">norfenfluramine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/317">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>20 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Agitation and drowsiness, confusion, flushing, tremor (or shivering), fever, sweating, abdominal pain, hyperventilation, and dilated non-reactive pupils seem frequent in fenfluramine overdosage. Reflexes may be either exaggerated or depressed and some patients may have rotary nystagmus. Tachycardia may be present, but blood pressure may be normal or only slightly elevated. Convulsions, coma, and ventricular extrasystoles, culminating in ventricular fibrillation, and cardiac arrest, may occur at higher dosages. Less than 5 mg/kg are toxic to humans. Five-ten mg/kg may produce coma and convulsions. Reported single overdoses have ranged from 300 to 2000 mg; the lowest reported fatal dose was a few hundred mg in a small child, and the highest reported nonfatal dose was 1800 mg in an adult. Most deaths were apparently due to respiratory failure and cardiac arrest. Toxic effects will appear within 30 to 60 minutes and may progress rapidly to potentially fatal complications in 90 to 240 minutes. Symptoms may persist for extended periods depending upon the dose ingested.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9868</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7004</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5138</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5934</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7404</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8506</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6781</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.8859</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8616</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7253</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5205</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5219</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6657</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8808
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6397
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.984
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.1255 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9666
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7811
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01063">Acetophenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01246">Alimemazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00392">Ethopropazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00623">Fluphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Fenfluramine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01306">Insulin Aspart</a></td><td>Fenfluramine increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01307">Insulin Detemir</a></td><td>Fenfluramine increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01309">Insulin Glulisine</a></td><td>Fenfluramine increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00902">Methdilazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Risk of serotoninergic syndrome</td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms.</td></tr><tr><td><a href="/drugs/DB00420">Promazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms.</td></tr><tr><td><a href="/drugs/DB01608">Propericiazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms.</td></tr><tr><td><a href="/drugs/DB00777">Propiomazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00372">Thiethylperazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00508">Triflupromazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Risk of serotoninergic syndrome</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>